Kornimate/medical-research-clean huggingface dataset:
child to adult neurodevelopment in gene expanded huntington's disease

Conditions: Huntington's Disease

Summary: huntington's disease (hd) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. hd is caused by a triplet repeat (cag)expansion in the gene huntingtin (htt). this disease has classically been conceptualized as a neurodegenerative disease. however, recent evidence suggests that abnormal brain development may play an important role in the etiology of hd. huntingtin (htt)is expressed during development and through life. in animal studies, the htt gene has been shown to be vital for brain development. this suggests that a mutant form of htt (gene-expanded or cag repeats of 40 and above) would affect normal brain development. in addition, studies in adults who are gene-expanded for hd, but have not yet manifested the illness, (pre-hd subjects) have significant changes in the structure of their brain, even up to 20 years before onset of clinical diagnosis. how far back these changes are evident is unknown. one possibility is that these brain changes are present throughout life, due to changes in brain development,though initially associated with only subtle functional abnormalities. in an effort to better understand the developmental aspects of this brain disease, the current study proposes to evaluate brain structure and function in children, adolescents, and young adults (ages 6-30) who are at risk for developing hd - those who have a parent or grandparent with hd. brain structure will be evaluating using magnetic resonance imaging (mri) with quantitative measures of the entire brain, cerebral cortex, as well as white matter integrity via diffusion tensor imaging. brain function will be assessed by cognitive tests, behavioral assessment, and physical and neurologic evaluation. subjects that are gene-expanded (ge) will be compared to subjects who are gene non-expanded (gne). changes in brain structure and/or function in the ge group compared to the gne group would lend support to the notion that this disease has an important developmental component.


Eligibility criteria:
inclusion criteria: * family history of huntington's disease * age 6-30 years * age-appropriate knowledge of hd and personal risk exclusion criteria: * metal in body, including braces * history of head trauma, brain tumor, seizures, epilepsy * history of major surgery and/or significant ongoing medical issue(s)

Keywords: huntington's disease hd huntington disease
french survey on heart failure

Conditions: Heart Failure; Observational Study

Summary: heart failure is the most common heart disease with increasing incidence due to the aging of the population is improving the initial prognosis of various conditions that lead to more or less progressive heart failure. heart failure is of great variety of clinical and pathophysiological forms necessitating the creation of quality records to clarify each of these forms. many types of cardiomyopathies exist, some of which are infrequent but with specific care. at the french level, few data exist. in addition, the therapeutic management changes regularly. new european recommendations (endorsed by the french society of cardiology = fsc) were published in may 2012. many therapeutic approaches are being evaluated. the course of care and how to take non-drug load (network monitoring, rehabilitation ...) have become important issues that have hardly been analyzed by existing records. this also leads to better define the different forms of this disease, their natural history and methods of management applied in real life. the register of fsc follows the registry of the european society of cardiology (esc)"heart failure (hf) long term" (cctirs no. 11.355bis) with inclusions will be completed in november 2012. this new study aims to generate more accurate data on a number of points and be more representative for a wider selection of patients, the french level.

the recruitment period will be 24 months, with a day of inclusion for each week, which will be included both patients external consultant for chronic heart failure patients hospitalized in the cardiology department, during this day for acute heart failure. monitoring will be carried out 12 months during a consultation normally scheduled for this type of pathology with the cardiologist investigator. patients included in a decompensation will also follow up to 3 months

Eligibility criteria:
inclusion criteria: * patient with chronic hf or patient hospitalized foor acute hf de novo or not * patient who accept to participate by signing a informed consent exclusion criteria: * patient who deny to participate
cassia cinnamon for glucose uptake in young women

Conditions: Insulin Resistance; Impaired Glucose Tolerance; Prediabetes

Summary: the purpose of this study was to compare the acute effects of 5g of cassia cinnamon, 50 minutes of endurance exercise performed at 70% of the heart rate reserve (correlated to vo2max), and 5g of cellulose placebo on blood glucose, serum insulin and insulin sensitivity following an oral glucose tolerance test 3 hours after administration of each intervention.


Eligibility criteria:
inclusion criteria: * sedentary * bmi: 27-45 * dxa body fat % greater than 30% * 18-30 years of age * healthy * from the baylor university campus and surrounding community * regular sleep habits exclusion criteria: * not regular users of any species of cinnamon * not diagnosed with any metabolic disorder or chronic medical condition * not taking prescription medications for 2 months before the study * not taking ergogenic aids for 2 months before the study * not taking oral contraceptives for 2 months before the study * no iud placed for 2 months before the study

Keywords: cassia cinnamon blood glucose endurance exercise acute exercise overweight obesity women
protein-bound uremic retention solutes and long nocturnal hemodialysis: a longitudinal analysis

Conditions: End Stage Kidney Disease

Summary: study on intradialytic kinetics of protein-bound uremic retention solutes during long nocturnal hemodialysis

although remarkable progress has been made, chronic kidney disease still poses a major burden on both individual patients, as well as on society as a whole. there is a strong inverse relationship between decreasing renal function, as estimated by glomerular filtration rate, and mortality rate, especially death due to cardiovascular disease. the exact cause(s) remain to be elucidated. uremic toxins might play an important role. in the course of decreasing renal function the concentration of numerous intracellular and extracellular compounds vary from the non-uremic state. a still increasing number of uremic retention solutes are being identified. renal replacement strategies aim to remove potentially harmful substances from the body. traditionally much attention has been paid to small water-soluble molecules such as urea nitrogen and creatinine. based on the results of the recent hemo and ademex studies, increases of small water-soluble solute removal above the level reached with modern dialysis techniques (hd, pd) seem not to be advantageous with regard to patient outcome. these findings may point to the importance of other distinct groups of uremic retention solutes. in view of the data described above, protein-bound solutes might be good candidates. several advantages of long duration hemodialysis have been observed, including a better control of blood pressure by decreasing extracellular fluid volume, lowering peripheral vascular resistance and improving endothelium-dependent and -independent vasodilation. a normalization of heart rate variability and improvement of left-ventricular function was noted as well. furthermore, anemia control has been shown to be easier and several nutritional parameters improved in patients treated with long duration hd. the therapy results in higher small water-soluble solute removal, phosphate removal and greater elimination of larger molecules (e.g. β2-microglobulin). it seems an appealing question whether a better control of the serum levels of protein-bound solutes can be achieved by long duration (nocturnal) hemodialysis. this might be another advantage of this therapeutic modality, or may even in part explain the better outcome of patients treated this way. the study compares intermittent hemodialysis with long nocturnal hemodialysis with respect to serum concentrations of several protein bound uremic toxins, as well as solute removal.

Eligibility criteria:
inclusion criteria: * start hemodialysis during 2007 * age over 18 years * informed consent exclusion criteria: * non consent

Keywords: hemodialysis dialysis adequacy uremic retention solute
cross-education in arthroscopic rotator cuff repair: a randomized controlled trial

Conditions: Rotator Cuff Tears; Pain, Shoulder; Surgery

Summary: this randomized-controlled trial aims to investigate the efficacy of cross-education on function, pain, and range of motion, muscle strength and quality of life in patients who underwent arthroscopic rotator cuff repair.

fifty voluntary patients who underwent arthroscopic rotator cuff repair, aged between 35-64 years will be randomly divided into two groups: cross-education group and standard rehabilitation group. interventions will be applied for 16 sessions (twice a week for 8 weeks). the patients will be assessed at baseline, at the end of the 8-week intervention and 1-month follow-up. the pain on activity, at rest and at night will be assessed with visual analog scale (vas). active range of motion will be assessed with a digital goniometer. isometric muscle strength will be measured with a handheld dynamometer. the functional status will be evaluated by constant-murley score (cms) and american shoulder and elbow surgeons (ases) score. health-related quality of life will be assessed with short form-12 (sf-12). the global rating of change will be used to evaluate patient satisfaction.

Eligibility criteria:
inclusion criteria: being aged between 35-65 years having undergone arthroscopic rotator cuff repair surgery having the ability to read and write turkish exclusion criteria: revision surgery or previous shoulder surgery having undergone subscapularis tendon repair in addition to arthroscopic rotator cuff repair having scoliosis surgery or a health problem that will cause limitation in spinal mobility restriction of movement or absence of limb in the opposite upper extremity having frozen shoulder presence of glenohumeral instability having been diagnosed with thoracic outlet syndrome presence of upper extremity fracture or tumor having been diagnosed with cervical radiculopathy having been diagnosed with any malignant condition, systemic, neurological or rheumatological disease having a skin disease or hearing-vision problem that will affect the evaluation process
single ascending dose study of trn-157 in healthy subjects

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this single ascending dose study is to determine and evaluate the safety and tolerability of trn-157 in approximately 40 healthy subjects.


Eligibility criteria:
inclusion criteria: 1. subject has provided written informed consent 2. the subject is male or female 18 to 65 years of age 3. if the subject or subject's partner is of childbearing potential, a medically acceptable form of contraception will be 4. non-smoker 5. good general health 6. willing to abstain from alcohol, caffeine, and xanthine-containing beverages 7. the subject is compliant and available throughout the entire study period exclusion criteria: 1. current diagnosis, as per subject or investigator or screening assessment, of: 1. unstable or uncontrolled disease in any organ system (including cardiovascular) on present therapy 2. history of narrow angle glaucoma 3. history of alcohol abuse within the past 5 years 4. history of smoking within the past 6 months 5. positive result for the alcohol and/or drugs of abuse 6. weight \> 100 kg or \< 50 kg 7. clinically significant abnormal ecg 8. history of clinically significant (per the investigator) disease or disorder 9. any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results 10. abnormal vital signs defined as any of the following: * systolic blood pressure ≥ 140 mmhg * diastolic blood pressure ≥ 90mmhg 2. heart rate \ 85 beats per minute 3. fever or other clinically significant physical exam findings 4. current or history of clinically significant respiratory disease, including asthma, emphysema, chronic bronchitis, or cystic fibrosis 5. history or current symptom(s) of respiratory tract inflammation 6. inability to perform reproducible spirometry in accordance with american thoracic society (ats) guidelines 7. abnormal fev1, fvc, or fev1/fvc (fev1 or fvc \< 80% of predicted or fev1/fvc ratio \< 0.7) 8. fev1 variability \> 10% between study visits 9. female of childbearing potential with a positive serum pregnancy test or currently breastfeeding 10. currently being treated for hypertension or taking any other medications that affect blood pressure significantly 11. inability to perform acceptable, quality serial spirometry or any other study procedures 12. positive screen for hepatitis b surface antigen (hbsag), hepatitis c antibody, or hiv antibody
nitric oxide therapy for acute chest syndrome in sickle cell disease children

Conditions: Acute Chest Syndrome; Sickle Cell Disease

Summary: acute chest syndrome is a severe sickle cell disease complication in children requiring blood transfusion therapy to prevent acute respiratory failure and death. nitric oxide is a potent vasodilator that could reverse pulmonary vascular occlusion and restore normal oxygenation. the randomized trial will test that hypothesis.

acute chest syndrome is a severe sickle cell disease complication in children requiring blood transfusion therapy to prevent acute respiratory failure and death. nitric oxide is a potent vasodilator that could reverse pulmonary vascular occlusion and restore normal oxygenation. the randomized trial will test that hypothesis in a prospective randomized double-blind placebo controlled study. 50 children in two years will be included: 25 in each arm.

Eligibility criteria:
inclusion criteria: * child between 1 and 18 years old * sickle cell anemia or equivalent (sickle beta 0 thalassemia)whoe weight is between 10kg and 65kg * presenting acute chest syndrome as defined a new radiological infiltrate with tachypnea, respiratory discomfort, cough, chest wall pain and fever more than 38.5°c * hypoxaemia with transcutaneous oxygen saturation equal or less than 92% * informed consent signed by parents and approved by the child able to express his consent * insured by the national social security system or by the universal medical insurance * previous medical physical examination exclusion criteria: * respiratory distress with hypoxaemia with transcutaneous oxygen saturation equal or less than 92% under more than 5l/min of oxygen or 40% oxygen inhaled, hypercapnia signs 'sweating, altered consciousness, paco2 more than 60mmhg) with need of emergency exchange transfusion and/or tracheal intubation with mechanical ventilation * isolated acute asthmatic crisis * stroke or priapism with emergency acute transfusion needed * acute anemia with hemoglobin drop of more than 20% as compared to steady state hemoglobin * chronic long term transfusion therapy * nitric oxyde hypersensitivity * patients with right-left extra-pulmonary cardiac shunt * patient previously included in the protocol * patient participating in another interventional protocol * pregnancy or breast feeding

Keywords: nitric oxide
safety and efficacy of inhaled insulin in patients with diabetes and asthma or copd

Conditions: Diabetes Mellitus; Asthma; Pulmonary Disease, Chronic Obstructive

Summary: phase 3 , open-label, randomized study to evaluate the safety and efficacy of the lilly/alkermes inhaled insulin system compared to injected insulin in type 1 and type 2 diabetes patients with asthma or copd. patients will be treated for 12 months with a 2 month follow up period.


Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes * asthma or copd exclusion criteria: * current smoking habit
gene therapy for x-linked severe combined immunodeficiency (scid-x1)

Conditions: X-linked Severe Combined Immunodeficiency

Summary: x-linked severe combined immunodeficiency (scid-x1) is an inherited disorder that results in failure of development of the immune system in boys. this trial aims to treat scid-x1 patients using gene therapy to replace the defective gene.


Eligibility criteria:
inclusion criteria: 1. no hla identical (a,b,c,dr,dq) family donor and no hla identical unrelated donor available within 3 months of diagnosis or patients whose underlying clinical problems and prognosis would be significantly compromised by chemotherapy conditioning (including persisting pneumonitis, protracted diarrhoea requiring parental nutrition, ongoing visceral viral infection (herpes viruses, hsv,vzv,cmv, ebv or adenovirus), systemic bcg infection, virus-induced lymphoproliferation. 2. diagnosis of classical scid-x1 based on immunophenotype (absent, or reduced numbers of non-functional t lymphocytes) and confirmed by dna sequencing 3. parental/guardian voluntary consent 4. boys between the ages of 0 and 16

Keywords: x-linked severe combined immunodeficiency, gene therapy patients will be enrolled following diagnosis and referral to great ormond street immunology service.
the effect of preoperative and post operative misoprostol administration on intraoperative blood loss and postpartum hemorrhage in cs

Conditions: Post Partum Hemorrhage

Summary: • patients will be divided into two groups 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby the 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen then we will compare between two groups regarding * intaoperative blood loss * risk of postpartum hemorraghe in the first 24 hrs * hb pre and postoperative for all patients intraoperative blood loss will be estimated by the number and weight of soaked towels and amount of blood in suction unit

• patients will be divided into two groups 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby the 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen then we will compare between two groups regarding * intaoperative blood loss * risk of postpartum hemorraghe in the first 24 hrs * hb pre and postoperative for all patients intraoperative blood loss will be estimated by the number and weight of soaked towels and amount of blood in suction unit

Eligibility criteria:
inclusion criteria: women attending for elective cs. * age between 20-35 years. * normal placental site * normal coagulation profile * full term pregnancies(above 37 wks) * medically free * spinal anesthesia * living baby * average liquor by u/s exclusion criteria: * • women attending for emergency cs * .age below 20 or above 35 * abnormal placentation (placenta previa,accrete,increta or percreta) * women with coagulopathy * preterm pregnancies (before 37 wks) * medical disorder (hypertension,diabetes, endocrinal disorder) * general anathesia * iufd * oligo or polyhydraminos by u/s
t-regulatory cells in diabetic type two nephropathy

Conditions: Diabetic Nephropathy Type 2

Summary: diabetes mellitus is one of the most prevalent health problems worldwide. diabetic nephropathy has become the leading cause of end-stage kidney disease worldwide and is associated with an increased cardiovascular risk. traditionally, metabolic and hemodynamic factors are the main causes of renal lesions in patients with type two diabetes mellitus and diabetic nephropathy , both considered non-immune diseases. serial researches has demonstrated that diabetic nephropathy is a metabolic and hemodynamic disorder, with inflammation playing a vital role in the process.

it has been reported that glomerular basement membranes from diabetic rats induced significantly greater amounts of tumor necrotic factor-alpha and interleukin-1 than when these cells were incubated with basement membranes from non-diabetic rats. these new findings were the first to suggest that inflammatory cytokines may participate in the pathogenesis of diabetic nephropathy .cluster of differentiation 4 cells are believed to play central roles in modulating immune responses. tumor necrotic factor-alpha and interleukin-6, and induce inflammation in the pathogenesis of autoimmune diseases. t- regulatory cells exert immunosuppressive effects which are important on the maintenance of immune homeostasis by producing anti-inflammatory cytokines, such as interleukin-10 and transforming growth factor-b. aim of this work is to the role of t regulatory cells :( cluster of differentiation 4, cluster of differentiation 25,cluster of differentiation 127 , forkhead box p3 cells) in the different stages of diabetic nephropathy before hemodialysis initiation.

Eligibility criteria:
inclusion criteria: adult patients above 20 years diagnosed with type 2 diabetes mellitus and have microalbuminuria, macroalbuminuria or renal impairment exclusion criteria: patients with ischemic heart disease, any other autoimmune diseases, and hepatitis c or b positive patients. b-patients with diabetic nephropathy on dialysis therapy c- patients with any other causes for renal diseases such as glomerulonephritis
a study to assess the effect of pf-03526299 on lung function following an allergen challenge in asthmatic subjects

Conditions: Asthma

Summary: pf-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.


Eligibility criteria:
inclusion criteria: * males and females 18-60 years * mild asthma * atopic to allergens exclusion criteria: * unstable asthma * smokers or recent ex-smokers * recent allergen challenge

Keywords: asthma allergen challenge
hydrochloorthiazide and hypernatriaemie

Conditions: Hypernatraemia

Summary: acquired hypernatremia appears to be associated with mortallity in icu. to reduce hypernatremia and shorten the time of hypernatremia, we investigate the effect of hydrochloorthiazide compared to a placebo


Eligibility criteria:
inclusion criteria: * sodium \> 142 exclusion criteria: * no informed consent

Keywords: intensive care diuretics